On December 19, 2017 AbbVie (NYSE: ABBV) reported that it will participate in the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 4, 2018 (Press release, AbbVie, DEC 19, 2017, View Source [SID1234522701]). Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

ON December 19, 2017 Tanvex rported that its recently completed pharmacokinetics (PK) study of the company’s biosimilar product candidate, TX16, showed favorable results supporting PK similarity of TX16 and the reference product, US-licensed Avastin (Press release, Tanvex BioPharma, DEC 19, 2017, View Source [SID1234524595]). In a prospective, single dose, double blinded, parallel group study conducted in 69 healthy adult male subjects, the test to reference ratio of geometric least squares (LS) mean and corresponding 90% confidence interval (CI) for the primary endpoint, AUC 0-∝, were within the acceptance range of 80.00 to 125.00%. In addition the test to reference ratios of geometric LS means and corresponding 90% CIs of the other PK endpoints, AUC 0-t and C max, were also within the acceptance range of 80.00% to 125.00% demonstrating similar peak concentrations and extent of exposure between TX16 and Avastin.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Overall, both TX16 and Avastin were generally safe and well tolerated by the study subjects, with mild to moderate treatment-emergent adverse events and no severe or serious adverse events reported.

Avastin (bevacizumab) is a vascular endothelial growth factor-specific angiogenesis inhibitor approved in the US for the treatment of multiple indications in combination with other agents, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

According to IMS data, US sales of Avastin were US$3.1 billion in 2016.

On December 19, 2017 Johnson & Johnson (NYSE: JNJ) reported that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd, to review fourth-quarter results (Press release, Johnson & Johnson, DEC 19, 2017, View Source [SID1234522707]). Alex Gorsky, Chairman and Chief Executive Officer; Dominic Caruso, Executive Vice President, Chief Financial Officer and Joseph J. Wolk, Vice President, Investor Relations, will host the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast is accessible at Johnson & Johnson’s website: www.investor.jnj.com. A webcast will be available approximately three hours after the conference call concludes.
By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
A replay of the conference call will be available until approximately 12:00 a.m. on January 31, 2018. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13674606.
Presentation materials will be available on www.investor.jnj.com.
The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.

On December 19, 2017 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the 36th Annual JP Morgan Health Care Conference on Monday, Jan. 8, at the Westin St. Francis in San Francisco. Alex Gorsky, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time)/5:30 p.m. (Eastern Time) (Press release, Johnson & Johnson, DEC 19, 2017, View Source [SID1234522708]). A subsequent Question & Answer session is scheduled for 3:00 p.m. (Pacific Time)/6:00 p.m. (Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast for both events will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A recording of the webcasts and podcasts will be available approximately two hours after each event.

On December 19, 2017 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:00 p.m. PT on January 8, 2018, in San Francisco, California (Press release, Myriad Genetics, DEC 19, 2017, View Source [SID1234522709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.